Generic forms of Plavix (clopidogrel bisulfate), a blood thinner which helps reduce the risk of heart attack and stroke, were approved by the FDA on Thursday, May 17.
The drug decreases the likelihood of clumping and clotting in blood platelets.
"For people who must manage chronic health conditions, having effective and affordable treatment options is important," said Keith Webber, Ph.D., deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research. "The generic products approved today will expand those options for patients."
Clopidogrel does not work in all patients and comes with several health risks including susceptibility to bruising, bleeding and difficulty in stopping spontaneous blood loss.
Apotex Corporation, Aurobindo Pharma, Mylan Pharmaceuticals, Roxane Laboratories, Sun Pharma, Teva Pharmaceuticals, and Torrent Pharmaceuticals have received approval for releasing 75 mg doses of clopidogrel.
For comments and feedback contact: editorial@rttnews.com
Health News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.